Tern plc: £3m facility ‘reflects confidence in underlying businesses’ says Progressive

Tern plc
[shareaholic app="share_buttons" id_name="post_below_content"]

Tern Plc (LON:TERN) has successfully negotiated a new funding facility with an investor to provide up to £3m, available for up to 36 months, with an initial £0.5m drawn down.

Progressive Equity Research commented:

The credit facility is intended to protect Tern’s commercial position by supporting further growth and investment in its current portfolio companies. The facility will also strengthen Tern’s negotiating position and moves the company closer to a self-financing model. We see this funding as a sensible move as Tern continues to mature its position and offering. Tern also hosted a Q&A session with Board members Al Sisto and Ian Ritchie, and we reiterate some of the key messages discussed.

▪ New funding structure. Draw down amounts can be repaid either in cash, using proceeds of a full or partial exit of one of its portfolio companies, or alternatively via conversion rights and the issue of new ordinary shares. However, the investor retains the option for the first 10 days following a non-cash payment for the drawdown to be satisfied through the sale of Wyld shares, from the Wyld Escrow facility. The investor will receive warrants equal to 50% of each drawdown. Following the initial advance, the investor received warrants with an exercise price of 6.79p (a 6% premium to the FY22 NAV of 6.4p); if exercised this would raise £375k.

▪ Tern’s management is looking to take advantage of Wyld’s success as a standalone company, following its IPO on NASDAQ First North in 2021. Wyld has built a significant order backlog since the commercial launch. Tern’s management will look to crystalise upside at appropriate stages to provide capital for investment elsewhere and to self-finance.

▪ Third-party investments reflect confidence in underlying businesses and reduce the reliance on Tern for capital. It has been year of two halves for Tern, with valuation uplifts reversed in H2 due to changing valuation metrics in the technology space. While we do not expect any near-term rebound in valuations, we believe that Tern remains well placed to help its portfolio through this phase of difficult macro conditions, and the funding arrangement strengthens Tern’s position in this regard.

▪ Tern’s model has built value and management is committed to providing access to returns through full or partial exits when shareholder value is maximised. Against the challenging macro backdrop, particularly for tech companies, Tern’s underlying metrics are improving. In our view, Tern’s funding-to-exit model requires patience as it navigates economic difficulties: we see the strong recurring revenue growth attracting additional strategic interest and look forward to positive newsflow.

Share on:
Find more news, interviews, share price & company profile here for:

Tern Plc secures extension on £120,000 loan balance

Tern PLC has extended the repayment date of its loan facility to 11 September 2026, providing additional flexibility as it plans funding for investee companies. £120,000 plus monthly interest remains payable following a partial repayment.

Tern Plc issues 78.2m shares following Open Offer

Tern Plc announced valid acceptances for 78,163,662 Open Offer Shares at 0.40 pence per share, generating gross proceeds of about £312,654. The enlarged share capital will total 750,877,367 ordinary shares upon admission to AIM.

Fundamental XR expands access to immersive training with web-enabled platform

Its new Immersive Web platform brings immersive training into the browser, lowering adoption barriers and broadening enterprise reach.

GLP-1 receptor agonists: Strategic market shift

Rapid uptake, evolving regulation and digital integration are reshaping the investment case for metabolic health therapies.

The Cyber Resilience Act forces a security reset for connected device makers

Device Authority helps manufacturers operationalise Cyber Resilience Act compliance through automated device identity and secure update management.

Pharmaceutical groups move closer to the consumer in strategic marketing reset

Pharmaceutical marketing is shifting towards direct consumer engagement, reshaping how companies compete and manage risk in a digital environment.

Search

Search